D-0640-2020 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0640-2020 was initiated by Glenmark Pharmaceuticals Inc., USA on Dec 17, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product. The recall status is ongoing. Affected quantity: 217,956 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 15, 2020
Initiation Date
Dec 17, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
217,956 bottles

Product description

Glenmark Ranitidine Tablets USP 150 mg Rx Only 100 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ NDC 68462-248-01

Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Distribution pattern

Natiowide

Code information

7701033A 7701826A 7702344A 7702345A 7702489A 7702706A 7702707A 7702708A 7702858A 7702859A 7702860A 7702928A 7702929A 7703196A 7703634A 7704492A 7704493A 7705159A 19190289 19190342 19190372

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0640-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0640-2020. Report a data issue: hello@regdatalab.com.